These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29635054)

  • 1. Current regulatory requirements and practical approaches for stability analysis of pharmaceutical products: A comprehensive review.
    Sengupta P; Chatterjee B; Tekade RK
    Int J Pharm; 2018 May; 543(1-2):328-344. PubMed ID: 29635054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stability testing requirements for vaccines--draft guidelines of the International Conference on Harmonization.
    Haase M
    Dev Biol Stand; 1996; 87():309-18. PubMed ID: 8854031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Forced degradation studies of biopharmaceuticals: Selection of stress conditions.
    Tamizi E; Jouyban A
    Eur J Pharm Biopharm; 2016 Jan; 98():26-46. PubMed ID: 26542454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A validated stability-indicating RP-HPLC method for levofloxacin in the presence of degradation products, its process related impurities and identification of oxidative degradant.
    Lalitha Devi M; Chandrasekhar KB
    J Pharm Biomed Anal; 2009 Dec; 50(5):710-7. PubMed ID: 19632800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Forced degradation of therapeutic proteins.
    Hawe A; Wiggenhorn M; van de Weert M; Garbe JH; Mahler HC; Jiskoot W
    J Pharm Sci; 2012 Mar; 101(3):895-913. PubMed ID: 22083792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory aspects of stability testing in Europe.
    Matthews BR
    Drug Dev Ind Pharm; 1999 Jul; 25(7):831-56. PubMed ID: 10459489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of validated stability-indicating assay methods--critical review.
    Bakshi M; Singh S
    J Pharm Biomed Anal; 2002 Jun; 28(6):1011-40. PubMed ID: 12049968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical Approaches to Forced Degradation Studies of Vaccines.
    Hasija M; Aboutorabian S; Rahman N; Ausar SF
    Methods Mol Biol; 2016; 1403():853-66. PubMed ID: 27076171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guidelines for the practical stability studies of anticancer drugs: a European consensus conference.
    Bardin C; Astier A; Vulto A; Sewell G; Vigneron J; Trittler R; Daouphars M; Paul M; Trojniak M; Pinguet F;
    Ann Pharm Fr; 2011 Jul; 69(4):221-31. PubMed ID: 21840442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A validated stability-indicating UPLC method for desloratadine and its impurities in pharmaceutical dosage forms.
    Rao DD; Satyanarayana NV; Malleswara Reddy A; Sait SS; Chakole D; Mukkanti K
    J Pharm Biomed Anal; 2010 Feb; 51(3):736-42. PubMed ID: 19815361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A critical assessment of the ICH guideline on photostability testing of new drug substances and products (Q1B): Recommendation for revision.
    Baertschi SW; Alsante KM; Tønnesen HH
    J Pharm Sci; 2010 Jul; 99(7):2934-40. PubMed ID: 20135694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WHO Expert Committee on specifications for pharmaceutical preparations.
    World Health Organ Tech Rep Ser; 1996; 863():1-194. PubMed ID: 8952445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of stability study designs.
    Lin TY; Chen CW
    J Biopharm Stat; 2003 Aug; 13(3):337-54. PubMed ID: 12921386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advice on Degradation Products in Pharmaceuticals: A Toxicological Evaluation.
    Melo SR; Homem-de-Mello M; Silveira D; Simeoni LA
    PDA J Pharm Sci Technol; 2014 5/6; 68(3):221-238. PubMed ID: 25188345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability post-licensure: compatibility container content - a practical case study.
    Duchêne M; Jeanmart L; Slegers B
    Biologicals; 2009 Nov; 37(6):407-9; discussion 421-3. PubMed ID: 19717309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International Conference on Harmonisation: guidance on Q1D bracketing and matrixing designs for stability testing of new drug substances and products; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jan; 68(11):2339-40. PubMed ID: 12532979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceutical Forced Degradation (Stress Testing) Endpoints: A Scientific Rationale and Industry Perspective.
    Zelesky T; Baertschi SW; Foti C; Allain LR; Hostyn S; Franca JR; Li Y; Marden S; Mohan S; Ultramari M; Huang Z; Adams N; Campbell JM; Jansen PJ; Kotoni D; Laue C
    J Pharm Sci; 2023 Dec; 112(12):2948-2964. PubMed ID: 37690775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International regulatory requirements for genotoxicity testing for pharmaceuticals used in human medicine, and their impurities and metabolites.
    Galloway SM
    Environ Mol Mutagen; 2017 Jun; 58(5):296-324. PubMed ID: 28299826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine stability study design and analysis to support product licensure.
    Schofield TL
    Biologicals; 2009 Nov; 37(6):387-96; discussion 421-3. PubMed ID: 19717312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of a quality-by-design approach to justify removal of the HPLC weight % assay from routine API stability testing protocols.
    Skrdla PJ; Wang T; Antonucci V; Dowling T; Ge Z; Ellison D; Curran J; Mohan G; Wyvratt J
    J Pharm Biomed Anal; 2009 Dec; 50(5):794-6. PubMed ID: 19596534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.